Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 7/20 | 0.49 |
| ▸ | CREBBP | Q92793 | 6/20 | 0.45 |
| ▸ | PIM1 | P11309 | 3/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 2/20 | 0.35 |
| ▸ | EP300 | Q09472 | 1/20 | 0.35 |
| ▸ | CECR2 | Q9BXF3 | 1/20 | 0.35 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12404157 | 0.86 | AXL (0.47) | AXLCREBBPPIM1MAPK1SIGMAR1 | |
| SCHEMBL17673271 | 0.77 | AXL (0.59) | AXLCREBBPBRD4EP300CECR2 | |
| SCHEMBL2273882 | 0.76 | AXL (0.41) | AXLPIM1BRD4 | |
| SCHEMBL26204527 | 0.75 | AXL (0.51) | AXLCREBBPPIM1MAPK1BRD4 | |
| SCHEMBL21404464 | 0.75 | CREBBP (0.40) | AXLCREBBPPIM1SIGMAR1BRD4 | |
| SCHEMBL2281142 | 0.74 | AXL (0.63) | AXLPIM1MAPK1 | |
| SCHEMBL4460005 | 0.73 | AXL (0.42) | AXLCREBBPPIM1HSD17B10BRD4 | |
| SCHEMBL6952100 | 0.72 | SPR (0.46) | MAPK1HSD17B10ADORA2A | |
| SCHEMBL30924204 | 0.72 | SPR (0.46) | MAPK1HSD17B10ADORA2A | |
| SCHEMBL6950131 | 0.71 | HSD17B10 (0.40) | HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250127792-A1 | IMIDAZOPIPERAZINE INHIBITORS OF TRANSCRIPTION ACTIVATING PROTEINS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2025-04-24 | — | — | US | disclosed |
| US-12186324-B2 | Imidazopiperazine inhibitors of transcription activating proteins | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-01-07 | — | — | US | disclosed |
| CN-112165944-B | Imidazopiperazine inhibitors of transcriptional activator proteins | 德州大学系统董事会 | 2024-04-09 | — | — | CN | disclosed |
| US-20230008047-A1 | IMIDAZOPIPERAZINE INHIBITORS OF TRANSCRIPTION ACTIVATING PROTEINS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2023-01-12 | — | — | US | disclosed |
| US-11058688-B2 | Imidazopiperazine inhibitors of transcription activating proteins | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-07-13 | — | — | US | disclosed |
| EP-3773587-A1 | IMIDAZOPIPERAZINE INHIBITORS OF TRANSCRIPTION ACTIVATING PROTEINS | Board of Regents, The University of Texas System (US) | 2021-02-17 | — | — | EP | disclosed |
| CN-112165944-A | Imidazopiperazine inhibitors of transcriptional activator proteins | 德州大学系统董事会 | 2021-01-01 | — | — | CN | disclosed |
| WO-2019191667-A1 | IMIDAZOPIPERAZINE INHIBITORS OF TRANSCRIPTION ACTIVATING PROTEINS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2019-10-03 | — | — | WO | disclosed |
| WO-2019191667-A1 | IMIDAZOPIPERAZINE INHIBITORS OF TRANSCRIPTION ACTIVATING PROTEINS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2019-10-03 | — | — | WO | disclosed |
| US-20190298729-A1 | IMIDAZOPIPERAZINE INHIBITORS OF TRANSCRIPTION ACTIVATING PROTEINS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2019-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11058688-B2 | Imidazopiperazine inhibitors of transcription activating proteins | EP300, CREBBP, RBBP7 | AXL 4678/4885CREBBP 2/4885PIM1 1435/4885 |
| US-20230008047-A1 | IMIDAZOPIPERAZINE INHIBITORS OF TRANSCRIPTION ACTIVATING PROTEINS | EP300, CREBBP, RBBP7 | AXL 4678/4885CREBBP 2/4885PIM1 1435/4885 |
| US-20250127792-A1 | IMIDAZOPIPERAZINE INHIBITORS OF TRANSCRIPTION ACTIVATING PROTEINS | EP300, CREBBP, RBBP7 | AXL 4678/4885CREBBP 2/4885PIM1 1435/4885 |
| US-12186324-B2 | Imidazopiperazine inhibitors of transcription activating proteins | EP300, CREBBP, RBBP7 | AXL 4678/4885CREBBP 2/4885PIM1 1435/4885 |
| US-20190298729-A1 | IMIDAZOPIPERAZINE INHIBITORS OF TRANSCRIPTION ACTIVATING PROTEINS | EP300, CREBBP, RBBP7 | AXL 4678/4885CREBBP 2/4885PIM1 1435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.